Phase
Condition
Carpal Tunnel Syndrome
Nerve Injury
Neuropathy
Treatment
N/AClinical Study ID
Ages > 18 All Genders
Study Summary
Eligibility Criteria
Inclusion
Inclusion Criteria:
for the retrospective phase are:
Patients with the established diagnosis of CTS.
Bilateral involvement of carpal tunnel established between the 1st January 2021 andthe 31st December 2024 (both patients who underwent CTS surgical intervention andwithout it are enrolled).
Age ≥ 18 years at the time of CTS diagnosis.
Provided written informed consent for the prospective phase of the study (includingmolecular genetic testing).
Presence of ≥1 of the following features (red flags): a. CIDP or polyneuropathy of unknown etiology in the family history; b. Spinal canalstenosis of the lumbar region; c. Autonomic dysfunction, defined by the presence of ≥1 of the following symptoms - i. Gastrointestinal complaints (constipation, chronicdiarrhea, or both); ii. Erectile dysfunction; iii. Orthostatic hypotension; d. Gaitdisorders; e. Sweating disorders, anhidrosis. f. Paresthesia and burning of the skinof the distal extremities g. Distal symmetrical paresis h. Hypotrophy andhypotension of limb muscles, areflexia i. Biceps tendon rupture j. Aortic valvestenosis k. Diagnosis of HFpEF l. Unexplained weight loss ≥5 kilos at any timepoint since the onset of symptoms ofCTS; m. Left ventricular hypertrophy (based on electro- or echocardiographiccriteria documented in the patient's medical record); n. Heart rhythm disorders; o.Renal abnormalities, defined by ≥1 of the following features - i. Documenteddiagnosis of chronic kidney disease (CKD); ii. Decreased estimated glomerularfiltration rate (eGFR <60 mL/min/1.73m2); iii. Increased serum creatinine (SCr)above reference range of the local laboratory; iv. Albuminuria (≥30 mg/g ofcreatinine or ≥30 mg/24h); v. Proteinuria (according to urinalysis results); p.Ophthalmology disorder defined by ≥1 of the following features - i. Vitreous bodyinclusions (opacification); ii. Glaucoma; iii. Pupillary disorders; iv. Vitrectomy
Absence of previously established ATTR PN diagnosis (ICD-10 code Е85.1, "Neuropathichereditary familial amyloidosis").
Exclusion
Exclusion Criteria:
Participation in any interventional trial within the period since identification ofbilateral involvement of carpal tunnel until the end of current study. The following criteria apply for non-inclusion of patients into the prospective partof the study:
Previously performed TTR genetic testing;
Verified B12 deficiency;
History of alcohol abuse according to the patient's medical record.
Study Design
Study Description
Connect with a study center
Research Site
Irkutsk,
Russian FederationActive - Recruiting
Research Site
Kazan,
Russian FederationActive - Recruiting
Research Site
Krasnodar,
Russian FederationActive - Recruiting
Research Site
Makhachkala,
Russian FederationActive - Recruiting
Research Site
Moscow,
Russian FederationActive - Recruiting
Research Site
Nizhny Novgorod,
Russian FederationActive - Recruiting
Research Site
Saint-Petersburg, 194354
Russian FederationSite Not Available
Research Site
Samara,
Russian FederationActive - Recruiting
Research Site
Yekaterinburg,
Russian FederationActive - Recruiting
Not the study for you?
Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.